The use of Actovegir for prevention of post-stroke cognitive impairment


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Stroke remains one of the most common causes of death worldwide and the third most important cause of disability. Post-stroke cognitive impairment (PSCI) of varying severity is detected in 40-70% of stroke patients. Cognitive impairment slows the process of functional recovery after a stroke. One of the most promising areas in the treatment of PSCI is the use of drugs with neurotrophic action. A large international, randomized, placebo-controlled ARTEMIS study has been devoted to the evaluation of the efficacy of actovegin in PSCI. The study found a statistically significant difference in the primary endpoint, a change in the ADAS-Cog + score at 6 months of treatment in the Actovegin group compared to placebo, indicating the effectiveness of the drug in improving cognitive function in stroke patients. Based on the results of an international randomized placebo-controlled ARTEMIS study, it can be concluded that the use of Actovegin in patients with acute ischemic stroke improves the prognosis for the recovery of cognitive functions, and, consequently, the prognosis of all rehabilitation activities conducted in both acute and early recovery period of stroke.

全文:

受限制的访问

作者简介

E. Koltsova

FSBEI HE RNSMU n.a. N.I. Pirogov of RMH; SRI of Cerebrovascular Pathology and Stroke

Email: koltsovaevgenia@rambler.ru

参考

  1. Feigin V.L., Forouzanfar M.H., Krishnamurthi R., et al; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245-54.
  2. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380: 2095-128.
  3. Murray C.J., Vos T., Lozano R., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197-223.
  4. Гусев Е.И., Скворцова В.И., Стаховская Л.В. Эпидемиология инсульта в России. Журн. неврологии и психиатрии. Инсульт. 2003; 8:4-9.
  5. Rajan K.B., Aggarwal N.T., Wilson R.S., et al. Association of cognitive functioning, incident stroke, and mortality in older adults. Stroke. 2014;45:2563-67.
  6. Leys D., Pasquier F. Post-stroke dementia. VASCOG, San Antonio, 2007; Tatemichi T.K., Desmond D.W., Mayeux R., et al. Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology. 1992;42:1185-93.
  7. Bowler J.V., Hachinski V. The concept of vascular cognitive impairment. T. rkinjuntti, S. Gauthier, eds. Vascular cognitive impairment. Martin. Dunitz 2002;9-26.
  8. Pendlebury S.T., Rothwell P.M. Prevalence, incidence, and factors associated with prestroke and post-stroke dementia: a systematic review and meta-analysis. Lancet. Neurol. 2009;8:1006-18.
  9. Leys D., Henon H., Mackowiak-Cordoliani M.A., Pasquier F. Poststroke dementia. Lancet. Neurol. 2005;752-59.
  10. Захаров В.В., Вахнина Н.В. Инсульт и когнитивные нарушения. Неврология, нейропсихиатрия и психосоматика. 2011;2:8-16.
  11. Brainin M., Tuomilehto J., Heiss W.D., et al. Post Stroke Cognition Study Group. Post-stroke cognitive decline: an update and perspectives for clinical research. Eur. J. Neurol. 2015;22:229-38, e13.
  12. Lakhan S.E., Kirchgessner A., Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J. Transl. Med. 2009;7:97.
  13. Ritter A., Pillai J.A. Treatment of vascular cognitive impairment. Curr. Treat Options Neurol. 2015;17:367.
  14. Преображенская И.С., Яхно Н.Н. Сосудистые когнитивные нарушения: клинические проявления, диагностика, лечение. Неврол. журн. 2007;12(5):45-50.
  15. Machicao F., Muresanu D.F., Hundsberger H., et al. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. J. Neurol. Sci. 2012;322:222-27.
  16. Kuninaka T., Senga Y., Senga H., Weiner M. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. J. Cell. Physiol. 1991;146:148-55.
  17. Elmlinger M.W., Kriebel M., Ziegler D. Neuroprotective and anti-oxidative effects of the hemodialysate Actovegin on primary rat neurons in vitro. Neuromolecular. Med. 2011; 13:266-74.
  18. Шмырев В.И., Остроумова О.Д., Боброва Т.А. Возможности препарата Актовегин в профилактике и лечении деменции. РМЖ. 2003;11(4):216-20.
  19. Hoyer S., Betz K. Elimination of the delayed postischemic energy deficit in cerebral cortex and hippocampus of aged rats with a dried, deproteinized blood extract (Actovegin). Arch. Gerontol. Geriatr. 1989;9:181-92.
  20. Krüger G., Quadbeck G. The electroencephalogram of the rat in oxygen deficiency as an indicator of drug effects on cerebral metabolism. Arzneimittelforschung. 1972;22:451-56.
  21. Lanner G., Argyropoulos. Pharmacological effect of Solcoseryl on the metabolism of the brain. Animal experiments and clinical research. Wien Med. Wochenschr. 1975;125:681-85.
  22. Meilin S., Machicao F., Elmlinger M. Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia. J. Cell. Mol. Med. 2014;18:1623-30.
  23. Saletu B., Küfferle B., Anderer P., et al. EEGbrain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol. Eur. Neuropsychopharmacol. 1990;1:27-36.
  24. Semlitsch H.V., Anderer P., Saletu B., Hochmayer I. Topographic mapping of cognitive event-related potentials in a double-blind, placebocontrolled study with the hemoderivative Actovegin in age-associated memory impairment. Neuropsychobiology. 1990;24:49-56.
  25. Jansen W., Brueckner G.W. Лечение хронической цереброваскулярной недостаточности с использованием драже Актовегин форте (двойное слепое плацебо-контролируемое исследование). РМЖ. 2002; 10(12-13):543-47.
  26. Saletu В., Grunberger J., Linzmayer L., Anderer P., Semlitsch H.V. EEG Brain Mapping and Psychometry in age-associated memory impairment after acute and 2-week infusion with the impairment after acute and 2-week infusion with the hemoderivative Actovegin: double-blind, placebo-controlled trials. Neuropsychobiol. 1990-91;24:135-48.
  27. Semlitsch H.V., Anderer P., Saletu B., Hochmayer I. Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in age-associated memory impairment. Neurophychobiol. 1990-91;24;49-56.
  28. Захаров В.В., Сосина В.Б. Применение антигипоксантов в лечении когнитивных нарушений у больных сахарным диабетом. Неврол. журн. 2008;5:39-43.
  29. Скоромец А.А., Ковальчук В.В. Анализ эффективности различных лекарственных препаратов в лечении инсультов. Сб. научно-практических статей «Актовегин в неврологии». М., 2002. С. 152-64.
  30. Федин А.И., Румянцева С.А. Антиоксидантная терапия нарушений мозгового кровообращения. Лечение нервных болезней. 2001; 2:7-12.
  31. Федин А.И., Румянцева С.А. Принципы антигипоксической терапии у больных с инсультом. Интенсивная терапия ишемического инсульта. Руководство для врачей. М., 2004. С. 160-251.
  32. Derev'yannykh E.A., Bel'skaya G.N., Knoll E.A., et al. Experience in the use of Actovegin in the treatment of patients with cognitive disorders in the acute period of stroke. Neurosci. Behav. Physiol. 2008; 38:873-75.
  33. Shamalov N.A., Stakhovskaia L.V., Shetova I.M., et al. Efficacy and safety of the combined therapy with citicholine and actovegin in the acute period of ischemic stroke. Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova. 2010;110(9 pt. 2):13-7.
  34. Sondergard S.D., Dela F., Helge J.W., Larsen S. Actovegin, a non-prohibited drug increases oxidative capacity in human skeletal muscle. Eur. J. Sport. Sci. 2016; 16:801-7.
  35. Actovegin 80 mg Injection Solution - Summary of Product Characteristics (SPC). http://www. Pharmazie.Com/graphic/a/17/2-00017.Pdf. AccessedNovember 15, 2016.
  36. Ramipril 1.25 mg Capsules - Summary of Product Characteristics (SPC). https://www. Medicines.Org.Uk/emc/medicine/24132. AccessedNovember 15, 2016.
  37. Memantine Accord 20 mg Film-Coated Tablets - Summary of Product Characteristics (SPC). https://www.Medicines.Org.Uk/emc/ medicine/28669. Accessed November 15, 2016.
  38. Guekht A., Skoog I., Korczyn A.D., et al. A randomised, double-blind, placebo-controlled trial of Actovegin in patients with post-stroke cognitive impairment: ARTEMIDA Study Design. Dement. Geriatr. Cogn. Dis. Extra. 2013;3: 459-67.
  39. Burton L., Tyson S.F. Screening for cognitive impairment after stroke: a systematic review of psychometric properties and clinical utility. J. Rehabil. Med. 2015;47:193-203.
  40. Pendlebury S.T., Mariz J., Bull L., et al. and MMSE versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Neuropsychological Battery after TIA and stroke. Stroke. 2012;43: 464-69.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##